Human flavin-containing monooxygenases

Annual Review of Pharmacology and Toxicology

Volumn 46, Issue , 2006, Pages 65-100

  Cashman, John R ^a   Zhang, Jun ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Amine and sulfide oxygenation; Clinical relevance; Drug development; Polymorphisms

Indexed keywords

CELECOXIB; CHLORPROMAZINE; DIMETHYLANILINE MONOOXYGENASE; DISULFIRAM; IMIPRAMINE; ORPHENADRINE; PHENOTHIAZINE; STREPTOZOCIN; SULINDAC; SULINDAC SULFIDE; THIAMAZOLE;

ADOLESCENT; ADULT; AGE; AGED; ALLELISM; CANCER; CHILD; DETOXIFICATION; DIABETES MELLITUS; DIET; DRUG DESIGN; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENE STRUCTURE; GENETIC VARIABILITY; HEMOCHROMATOSIS; HUMAN; HYPERTENSION; INFANT; MALE; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA SPLICING; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SPECIES DIFFERENCE; TRANSCRIPTION REGULATION;

DISEASE; FMN REDUCTASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA SPLICING; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP; TERMINOLOGY; VARIATION (GENETICS);

EID: 33144459248     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.46.120604.141043     Document Type: Review

References (174)

1. Cashman JR. 1997. Monoamine oxidase and flavin-containing monooxygenase. In Comprehensive Toxicology, ed. FP Guengerich, IG Snipes, A McQueen, AJ Gandolfi, 3:69-96. Cambridge, UK: Pergamon
2. Ziegler DM, Mitchell CH. 1972. Microsomal oxidase IV: properties of mixed-function amine oxidase isolated from pig liver microsomes. Arch. Biochem. Biophys. 150:116-25
3. Ziegler DM, Poulson LL. 1978. Hepatic microsomal mixed-function amine oxidase. Meth. Enzymol. 15:188-93
4. Cashman JR. 2000. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr. Drug Metab. 1:181-91
5. Cashman JR. 1995. Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. 8:165-81
6. Tynes RE, Sabourin PJ, Hodgson E. 1985. Identification of distinct hepatic and pulmonary forms of microsomal flavin-containing monooxygenase in the mouse and rabbit. Biochem. Biophys. Res. Commun. 126:1069-75
7. Williams DE, Ziegler DM, Nordin DJ, Hale SE, Masters BSS. 1984. Rabbit lung flavin-containing monooxygenase is immunochemically and catalytically distinct from the liver enzyme. Biochem. Biophys. Res. Commun. 125:116-22
8. Hines RN, Cashman JR, Philpot RM, Williams DE, Ziegler DM. 1994. The mammalian flavin-containing monooxygenase: molecular characterization and regulation of expression. Toxicol. Appl. Pharmacol 125:1-6
9. Lawton M, Cashman J, Cresteil T, Dolphin C, Elfarra A, et al. 1994. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys. 308:254-57
10. Phillips IR, Dolphin CT, Clair P, Hadley MR, Hutt AJ, et al. 1995. The molecular biology of the flavin-containing monooxygenase of man. Chem. Biol. Interact. 96:17-32
11. Hines RN, Hopp KA, Franco J, Saeian K, Begun FP. 2002. Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol. Pharmacol. 62:320-25
12. Beaty N, Ballou D. 1980. A kinetic investigation of liver microsomal mixed function amine oxidase. In Microsomes, Drug Oxidation, and Chemical Carcinogenesis, ed. MJ Coon, AH Conney, RW Estabrook, HV Gelboin, JR Gillette, PJ O'Brien, pp. 209-302. New York: Academic
13. Hodgson E, Levi PE. 1992. The role of the flavin-containing monooxygenase (EC 1.14.13.8) in the metabolism and mode of action of agricultural chemicals. Xenobiotica 22:1175-83
14. Krueger SK, Williams DE, Yueh MF, Martin SR, Hines RN, et al. 2002b. Genetic polymorphisms of flavin-containing monooxygenase (FMO). Drug Metab. Rev. 34:523-32
15. Rettie AE, Lawton MP, Sadeque AJM, Meier GP, Philpot RM. 1994. Prochiral sulfoxidation as a probe for multiple forms of the microsomal flavin-containing monooxygenase: studies with rabbit FMO1, FMO2, FMO3, and FMO5 expressed in Escherichia coli. Arch. Biochem. Biophys. 311:369-77
16. Cashman JR, Zhang J. 2002. Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab. Dispos. 30:1043-52
17. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA. 2004. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse; identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-30
18. Ziegler DM. 1990. Enzymes adapted for multisubstrate specificity trends. Pharmacol. Sci. 11:321-34
19. Lang DH, Yeung CK, Peter RM, Ibarra C, Gasser R, et al. 1998. Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem. Pharmacol. 56:1005-12
20. Cashman JR, Camp K, Fakharzadeh SS, Fennessey PV, Hines RN, et al. 2003. Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr. Drug Metabol. 4:151-70
21. Jakoby WB, Ziegler DM. 1990. The enzymes of detoxication. J. Biol. Chem. 265:20715-18
22. Poulsen LL. 1981. Organic sulfur substrates for the microsomal flavin-containing monooxygenase. In Reviews in Biochemical Toxicology, ed. E Hodgson, JR Bend, RM Philpot, pp. 33-49. North Holland: Elsevier
23. Decker CJ, Doerge DR, Cashman JR. 1992. Metabolism of benzimidazoline-2-thiones by rat hepatic microsomes and hog liver flavin-containing monooxygenase. Chem. Res. Toxciol. 5:726-33
24. Henderson MC, Krueger SK, Stevens JF, Williams DE. 2004. Human flavin-containing monooxygenase form 2 S-oxygenation: sulfenic acid formation from thioureas and oxidation of glutathione. Chem. Res. Toxicol. 17:633-40
25. Ziegler DM. 1993. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. 33:179-99
26. Ziegler DM, Pettit FH. 1964. Formation of an intermediate N-oxide in the oxidative demethylation of N,N-dimethylaniline catalyzed by liver microsomes. Biochem. Biophys. Res. Commun. 15:188-93
27. Shephard EA, Dolphin CT, Fox ME, Povey S, Smith R, Phillips JU. 1993. Localization of genes encoding three distinct flavin-containing monooxygenase to human chromosome 1g. Genomics 16:85-89
28. McCombie RR, Dolphin CT, Povey S, Phillips IR, Shepard EA. 1996. Localization of human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosomes 1g. Genomics 34:426-29
29. Atta-Asafo-Adjei E, Lawton MP, Philpot RM. 1993. Cloning, sequencing, distribution, and expression in Escherichia coli of flavin-containing monooxygenase IC1. Evidence for a third gene subfamiliy in rabbits. J. Biol. Chem. 268:9681-89
30. Lawton MP, Philpot RM. 1993. Functional characterization of flavin-containing monooxygenase 1B1 expressed in Saccharomyces cerevisiae and Escherichia coli and analysis of proposed FAD-and membrane-binding domains. J. Biol. Chem. 268:5728-34
31. Cashman JR. 2004. The implications of polymorphism in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov. Today 9:574-81
32. Ziegler DM, Poulsen LL. 1998. Catalytic mechanism of FMO-catalyzed N- and S-oxidations. In Drug Metabolism. Towards the Next Millennium, ed. N Gooderham, pp. 30-38. Amsterdam: ISO
33. Janmohamed A, Dolphin CT, Phillips IR, Shephard EA. 2001. Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450. Biochem. Pharmacol. 62:777-86
34. Janmohamed A, Hernandez D, Phillips IR, Shephard EA. 2004. Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenase (FMO's). Biochem. Pharmacol. 68:73-83
35. Koukouritaki SB, Simpson P, Yeung CK, Rettie AE, Hines RN. 2002. Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51:236-34
36. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, Philpot RM. 1995. Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit orthologs. Arch. Biochem. Biophys. 317:275-84
37. Shehin-Johnson S, Williams DE, Larsen-Su S, Stresser DM, Hines RN. 1995. Tissue-specific expression of flavin-containing monooxygenase (FMO) forms 1 and 2 in the rabbit. J. Pharmacol. Exp. Ther. 272:1293-99
38. Lattard V, Longin-Sauvageon C, Benoit E. 2003. Cloning, sequencing and tissue distribution of rat flavin-containing monooxygenase 4: two different forms are produced by tissue-specific alternative splicing. Mol. Pharmacol. 63:253-61
39. Cashman JR, Zhang J. 2005. Human flavin containing monooxygenase: quantification in human tissues. Toxicologist 84:1554 (Abstr.)
40. Mitchell SC, Zhang AQ, Barrett T, Ayesh R, Smith RL. 1997. Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populations. Pharmacogenetics 7:45-50
41. Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, Cashman JR. 2003. Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab. Dispos. 31:854-60
42. Cashman JR. 2002. Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics 3:325-39
43. Cashman JR. 2004. The role of flavin-containing monooxygenases in drug metabolism and development. Curr. Opin. Drug Discov. Dev. 6(4):486-93
44. Kang JH, Chung WG, Lee KH, Park CS, Kang JS, et al. 2000. Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population. Pharmacogenetics 10:67-78
45. Cashman JR, Zhang J, Leushner J, Braun S. 2001. Population distribution of human flavin-containing monooxygenase form 3: gene polymorphisms. Drug Metab. Dispos. 29:1629-37
46. Cashman JR, Akerman BR, Forrest SM, Treacy EP. 2000. Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab. Dispos. 28:169-73
47. Park CS, Kang JH, Chung WG, Yi HG, Pie JE, et al. 2002. Ethnic differences in allelic frequency of two flavin-containing monooxygenase 3 (FMO3) polymorphisms: linkage and effect on in vivo and in vitro FMO activities. Pharmacogenetics 12:77-80
48. Murphy HC, Dolphin CT, Jamohamed A, Holmes HC, Michelakakis H, et al. 2000. A novel mutation in the flavin-containing monooxygenase 3 gene, FMO3, that causes fish-odour syndrome: activity of the mutant enzyme assess by proton NMR spectroscopy. Pharmacogenetics 10:439-51
49. Cashman JR, Bi YA, Lin J, Youil R, Knight M, et al. 1997. Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem. Res. Toxicol. 10:837-41
50. Mitchell SC, Smith RL. 2001. Trimethylaminuria: the fish malodor syndrome. Drug Metab. Dispos. 29:517-21
51. Ayesh R, Smith RL. 1990. Genetic polymorphism of trimethylamine N-oxidation. Pharmacol. Ther. 45:387-401
52. Koukouritaki SB, Poch MT, Cabacungan ET, McCarver DG, Hines RN. 2005. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol. Pharmacol. 68:383-92
53. Cashman JR, Williams DE. 1990. Enantioselective 5-oxygenation of 2-aryl-1, 3-dithiolanes by rabbit lung enzyme preparations. Mol. Pharmacol. 37:333-39
54. Lemoine A, Williams DE, Cresteil T, Leroux JP. 1991. Hormonal regulation of microsomal flavin-containing monooxygenase: tissue dependent expression and substrate specificity. Mol. Pharmacol. 40:211-17
55. Dannon GA, Guengenrich FP, Waxman DJ. 1986. Hormonal regulation of rat liver microsomal enzymes. Role of gonadal steroids in programming, maintenance, and suppression of Δ-4-steroid-5-α-reductase, flavin-containing monooxygenase, and sex-specific cytochrome P450. J. Biol. Chem. 261:10728-35
56. Dixit A, Roche TE. 1984. Spectrophotometric assay of the flavin-containing monooxygenase and changes in its activity in female mouse liver with nutritional and diurnal conditions. Arch. Biochem. Biophys. 233:50-63
57. Heinz E, Hlavica P, Kiese M, Lipowsky G. 1970. N-oxygenation of arylamines in microsomes prepared from corpra lutea of the cycles and other tissues of the pig. Biochem. Pharmacol. 19:641-49
58. Luo Z, Hines RN. 2001. Regulation of flavin-containing monooxygenase 1 expression by ying yang 1 and hepatic nuclear factors 1 and 4. Mol. Pharmacol. 60:1421-30
59. Hines RN, Luo Z, Hopp KA, Cabacungan ET, Koukouritaki SB, McCarver DG. 2003. Genetic variability at the human FMO1 locus: significance of a basal promoter ying yang 1 element polymorphism (FMO1*6). Pharmacol. Exp. Ther. 306:1210-12
60. Ryn SD, Kang JH, Yi HG, Nahm CH, Park CS. 2004. Hepatic flavin-containing monooxygenase activity attenuated by cGMP-independent nitric oxide-mediated mRNA destabilization. Biochem. Biophys. Res. Commun. 324:409-16
61. Korsmeyer KK, Guan S, Yang Z, Falick AM, Ziegler DM, Cashman JR. 1998. N-glycosylation of pig flavin-containing monooxygenase form 1: determination of the site of protein modification by mass spectrometry. Chem. Res. Toxicol. 11:1145-53
62. Brunelle A, Bi YA, Russel B, Luy L, Berkman C, Cashman J. 1997. Characterization of two human flavin-containing monooxygenase (form 3) enzymes expressed in Escherichia coli as maltose binding protein fusions. Drug Metab. Dispos. 25:1001-7
63. Ryn SD, Yi HG, Cha YN, Kang JH, Kang JS, et al. 2004. Flavin-containing monooxygenase activity can be inhibited by nitric oxide-mediated S-nitrosylation. Life Sci. 75:2559-72
64. Overby LH, Carver GC, Philpot RM. 1997. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem. Biol. Interact. 106:29-45
65. Yeung CK, Lang DH, Thummel KE, Rettie AE. 2000. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Dispos. 28:1107-11
66. Lawton MP, Cashman JR, Cresteil T, Dolphin CT, Elfarra AA, et al. 1994. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch. Biochem. Biophys. 308:254-57
67. Cashman JR. 1999. In vitro metabolism: FMO and related oxygenations. In Handbook of Drug Metabolism, ed. TF Wolfe, pp. 477-506. Ann Arbor: Marcel Dekker
68. Lang DH, Rettie AE. 2000. In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 gene. Mol. Genet. Metab. 50(4):311-14
69. Stormer E, Roots I, Brockmoller J. 2000. Benzydamine N-oxygenation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br. J. Clin. Pharmacol. 50:553-61
70. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P III, Benowitz N. 1992. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nictoine N′-oxide. Chem. Res. Toxicol. 5:639-46
71. Cashman JR, Park SB, Yang ZC, Washington CB, Gomez DY, et al. 1993. Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine. Drug Metab. Dispos. 21:587-97
72. Mushiroda T, Douya R, Takahara E, Nagata O. 2000. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab. Dispos. 28:1231-37
73. Fang J. 2000. Metabolism of clozapine by rat brain: the role of flavin-containing monooxygenase (FMO) and cytochrome P450 enzymes. Eur. J. Drug Metab. Pharmacokinet. 25:109-14
74. Park SB, Jacob P III, Benowitz NL, Cashman JR. 1993. Stereoselective metabolism of (S)-(-)-nicotine in humans formation of trans-(S)-(-)-nicotine N-1′-oxide. Chem. Res. Toxicol. 6:880-88
75. Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. 2003. Trimethylaminuria and a human FMO3 mutation database. Hum. Mutat. 22:209-13
76. Cashman JR. 1998. Stereoselectivity in S- and N-oxygenation by the mammalian flavin-containing and cutochrome p-450 monooxygenses. Drug Metab. Rev. 30:675-707
77. Kim YM, Ziegler DM. 2000. Size limits of thiocarbamides accepted as substrates by human flavin-containing monooxygenase 1. Drug Metab. Dispos. 28:1003-6
78. Lomri N, Yang Z, Cashman JR. 1993. Regio- and stereoselective oxygenations by adult human liver flavin-containing monoxygenase 3. Comparision with Forms 1 and 2. Chem. Res. Toxicol. 6:800-7
79. Lomri N, Yang Z, Cashman JR. 1993. Expression in Escherichia coli of the flavin-containing monooxygenase D (form II) from adult human liver: determination of a distinct tertiary amine substrate specificity. Chem. Res. Toxicol. 6:425-29
80. Overby LH, Buckpitt AR, Lawton MP, Atta-Asafo-Adjei E, Schulze J, Philpot RM. 1995. Characterization of flavin-containing monooxygenase 5 (FMO5) cloned from human and guinea pig: evidence that the unique catalytic properties of FMO5 are not confined to the rabbit ortholog. Arch. Biochem. Biophys. 317:275-84
81. Pike MG, Mays DC, Macomber DW, Lipsky JJ. 2001. Metabolism of a disulfiram metabolite, S-methyl N,N-diethyldithiocarbamate, by flavin monooxygenase in human renal microsomes. Drug Metab. Dispos. 29:127-32
82. Furnes B, Feng J, Sommer SS, Schlenk D. 2003. Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab. Dispos. 31:187-93
83. Furnes B, Schlenk D. 2004. Evaluation of xenobiotic N- and S-oxidation by variant flavin-containing monooxygenase 1 (FMO1) enzymes. Toxicol. Sci. 78:196-203
84. Cashman JR. 1996. Human flavin-containing monooxygenases and drug metabolism. Proc. N. Am. ISSX Meet., 7th, pp. 20-24, October, San Diego (Abstr. No. 2)
85. Furnes B, Schlenk D. 2005. Extrahepatic metablolism of carbamate and organophosphate thioether compounds by the flavin-containing monooxygenase and cytochrome p450 systems. Drug. Metab. Dispos. 33:214-18
86. Yueh MF, Krueger SK, Williams DE. 1997. Pulmonary flavin-containing monoxygenase (FMO) in rhesus macaque: expression of FMO2 protein, mRNA and analysis of the Cdna. Biochim. Biophys. Acta. 1350:267-71
87. Whestine JR, Yueh MF, Hopp KA, McCarver DG, Williams DE, et al. 2000. Ethnic differences in human flavin-containing monooxygenase 2 (FMO2) polymorphisms: detection of expressed protein in African Americans. Toxicol. Appl. Pharmacol. 168:216-24
88. Dolphin CT, Beckett DJ, Janmohamed A, Cullingford TE, Smith RL, et al. 1998. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not of other primated, encodes a truncated, nonfunctional protein. J. Biol. Chem. 273:30599-607
89. Krueger SK, Siddens LK, Martin SR, Yu A, Pereira CB, et al. 2004. Differences in FMO2*1 allelic frequency between Hispanics of Puerto Rican and Mexican descent. Drug Metab. Dispos. 32:1337-40
90. Krueger SK, Siddens LK, Henderson MC, Andreasen EA, Tanguay RL, et al. 2005. Haplotype and functional analysis of four flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics. Pharmacogenetics 15(4):245-56
91. Krueger SK, Martin SR, Yueh MF, Pereira CB, Williams DE. 2002. Identification of active flavin-containing monooxygenase isoform 2 in human lung and characterization of expressed protein. Drug Metab. Dispos. 30:34-41
92. Henderson MC, Krueger SK, Siddens LK, Stevens JF, Williams DE. 2004. S-oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human lung flavin-containing monooxygenase 2. Biochem. Pharmacol. 68:959-67
93. Dolphin CT, Cullingford TE, Shephard EA, Smith RL, Phillips JR. 1996. Differential development and tissue-specific regulation of expression of the genes encoding three members of the flavin-containing monooxygenase family of man, FMO1, FMO3, and FMO4. Eur. J. Biochem. 235:683-89
94. Park CS, Chung WG, Kang JH, Roh HK. 1999. Phenotyping of flavin-containing monooxygenase using caffeine metabolism and genotyping of FMO3 gene in a Korean population. Pharmacogenetics 9:155-64
95. Mayatepek E, Flock B, Zschocke J. 2004. Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics 14:775-77
96. Mitchell SC, Smith RL. 2003. Trimethylamine and odorous sweat. J. Inherit. Metab. Dis. 26:415-16
97. Preti G, Lawley HJ, Hermann CA, Cowart BJ, Feldman RS, et al. 1995. Non-odor and oral aspects of oral malodor. In Bad Breath: Research Perspectives, ed. M Rosenberg, pp. 149-73. Ramat Aviv: Ramont Publ.
98. Zschocke J, Kohlmueller D, Quak E, Meissner T, Hoffmann GF, Mayatepek E. 1999. Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet 354:834-35
99. Lambert DM, Mamer OA, Akerman BR, Choiniere L, Gaudet D, et al. 2001. In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol. Genet. Metab. 73:224-29
100. Treacy EP, Akerman BR, Chow LML, Youil R, Bibeau C, et al. 1998. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet. 7:839-45
101. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. 1997. Missense mutations in flavin-containing monoxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat. Genet. 17:194-94
102. Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, et al. 1999. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin. Pharamcol. Ther. 66:431-38
103. Fujieda M, Yamazake H, Togashi M, Saito T, Kamataki T. 2003. Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab. Pharmacokin. 18:333-35
104. Dolphin CT, Janmohamed A, Smith RL, Shephard EA, Phillips IR. 2000. Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. Pharmacogenetics 10:799-807
105. Zhang J, Tran Q, Lattard V, Cashman JR. 2003. Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria. Pharmacogenetics 13:495-500
106. Zhang AQ, Mitchell SC, Smith RL. 1996. Exacerbation of symptoms of fish-odour syndrome during menstruation [letter]. Lancet 348:1740-41
107. Yamazaki H, Fujieda M, Togashi M, Saito T, Preti G, et al. 2004. Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of trimethylamine in Japanese trimethylaminuria patients. Life Sci. 74:2739-47
108. Yamazaki H, Fujieda M, Cashman JR, Kakataki T. 2005. Mild trimethylaminuria observed in a Japanese cohort with liver damage. Am. J. Med. 118:803-5
109. Lattard V, Zhang J, Cashman JR. 2004. Alternative processing events in human FMO genes. Mol. Pharmacol. 65:1517-25
110. Cherrington NJ, Falls JG, Rose RL, Clements KM, Philpot RM, et al. 1998. Molecular cloning, sequence, and expression of mouse flavin-containing monooxygenase. 1 and 5 (FMO1 and FMO5). J. Biochem. Mol. Toxicol. 12:205-12
111. Ohmi N, Yoshida H, Endo H, Hasegawa M, Akimoto M, Higuchi S. 2003. S-oxidation of S-methyl-esonarimod by flavin-containing monooxygenases in human liver microsomes. Xenobiotica 33:1221-31
112. Ziegler DM. 2003. An overview of the mechanism, substrate specificities, and structure of FMOs. Drug Metab. Rev. 34:503-11
113. Ziegler DM. 1980. Microsomal flavin-containing monooxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds. In Enzymatic Basis of Detoxication, ed. WB Jakoby, pp. 201-27. New York: Academic
114. Beaty NB, Ballou DP. 1981. The oxidative half-reaction of liver microsomal FAD-containing monooxygenase. J. Biol. Chem. 256:4619-25
115. Ziegler DM. 1982. Functional groups bearing sulfur. In Metabolism of Functional Groups, ed. WB Jakoby, JR Bend, J Caldwell, pp. 171-84. New York: Academic
116. Beaty NB, Ballou DP. 1981. The reductive half-reaction of liver microsomal FAD-containing monooxygenases. J. Biol. Chem. 256:4611-18
117. Poulson LL, Ziegler DM. 1979. The liver microsomal FAD-containing monooxygenases. Spectral characterization and kinetic studies. J. Biol. Chem. 254:6449-55
118. Cashman JR. 1991. Metabolism of tertiary amines by rat and hog liver microsomes: role of nonenzymatic Cope-elimination to an N-dealkylated product. Prog. Pharmacol. Clin. Pharmacol. 8:117-26
119. Kedderis GL, Rickert DE. 1985. Loss of rat liver microsomal cytochrome P450 during methimazole metabolism. Role of flavin-containing monooxygenase. Drug. Metab. Dispos. 13:58-61
120. Cerney MA, Hanzlik RP. 2005. Cyclopropylamine inaction of cytochromes P450: role of metabolic intermediate complexes. Biochem. Biophys. 436:265-75
121. Ziegler DM, Duffel MW, Poulsen LL. 1979. Studies on the nature and regulation of the cellular thio:disulphide potential. Ciba Found. Symp. 72:191-204
122. Cashman JR, Xiong Y, Lin J, Verhagen H, van Poppel G, et al. 1999. In itro and in vivo inhibition of human flavin-containing monooxygenase form 3 in the presence of dietary indoles. Biochem. Pharmacol. 58:1047-55
123. Clement B, Weide M, Ziegler DM. 1996. Inhibition of purified and membrane-bound flavin-containing monooxygenase 1 by (N, N-dimethylamino) stillbene carboxylates. Chem. Res. Toxicol. 9:599-604
124. Clement B. 2002. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab. Rev. 34:565-79
125. Hughes C, Dowling R. 1980. Speed of onset of adaptive mucosal hypoplasia and hypofunction in the intestine of parenterally fed rats. Clin. Sci. 59:317-27
126. Knodell RG, Steele NM, Cerro FB, Gross JB, Solomon TE. 1984. Effects of parenteral and enteral hyperalimentation on hepatic drug metabolism in the rat. J. Pharmacol Exp. Ther. 229:589-97
127. Knodell RG, Wood PG, Guegerich FP. 1989. Selective alteration of constitutive hepatic cytochrome P-450 enzymes in the rat during parental hyperalimentation. Biochem. Pharmacol. 38:3341-45
128. Cashman JR, Lattard V, Lin J. 2003. Effects of total parenteral nutrition and choline on hepatic flavin-containing and cytochrome P-450 monooxygenase activity in rats. Drug Metab. Dispos. 29:517-21
129. Dempsey D, Jacob P III, Benowitz NL. 2002. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J. Pharmacol. Exp. Ther. 301:594-98
130. Guyton AC. 1991. BP control: special role of the kidneys and body fluids. Science 252:1813-16
131. Lifton RP. 1996. Molecular genetics of human BP variation. Science 272:676-80
132. El-Alfy A, Larsen B, Schlenk D. 2005. Effect of cortisol and urea on flavin monooxygenase activity and expression in rainbow trout, Oncorhynchus mykiss. Mar. Environ. Res. 54:275-78
133. Schlenk D. 1993. A comparison of endogenous and exogenous substrates of the flavin-containing monooxygenases in aquatic organisms. Aquat. Toxicol. 26:157-62
134. Schlenk D. 1998. Occurrence of flavin-containing monooxygenases in non-mammalian eukaryotic organisms. Comp. Biochem. Physiol. 121C:185-95
135. Larsen BK, Schlenk D. 2002. Effect of urea and low temperature on the expression of flavin-containing monooxygenase in the liver and gill of rainbow trout. Fish Physiol. Biochem. 25:19-29
136. Lin J, Cashman JR. 1997. Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans oxime. Chem. Res. Toxicol. 10:842-52
137. Treacy E, Lambert D, Akerman BR, Yang H, Ryan S, et al. 2000. Polymorphisms of the flavin-containing monooxygenase 3 (FMO3) gene predispose to early onset essential hypertension in French Canadians. Am. J. Hum. Genet. 70:425-34
138. Akerman BR, Lemass H, Chow LM, Lambert DM, Greenberg C, et al. 1999. Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol. Genet. Metab. 68:24-31
139. Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J. 1998. Mutation of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet 7:839-45
140. Forrest SM, Knight M, Akerman BR, Cashman JR, Treacy EP. 2001. A novel deletion in the flavin-containing monooxygenase gene (FMO3) in a Greek patient with trimethylaminuria. Pharmacogenetics 11:169-74
141. Lin J, Cashman JR. 1997. N-oxygenation of phenethylamine to the trans-oxime by adult human liver flavin-containing monooxygenase and retroreduction of phenethylamine hydroxylamine by human liver microsomes. J. Pharmacol. Exp. Ther. 282:1269-79
142. Muckenthaler M, Roy CN, Angel CO, Miñana B, de Graaf J, et al. 2003. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat. Genet 34:102-7
143. Thun MJ, Henley SJ, Patrono C. 2002. Nonsteroidal anti-inflammatory drug as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94:252-66
144. Keller JJ, Giardiello FM. 2003. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. 2: S140-49
145. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, et al. 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 342:1946-52
146. Duggan DE, Hooke KF, Risley EA, Shen TY, Arman CG. 1977. Identification of the biologically active form of sulindac. J. Pharmacol. Exp. Ther. 201:8-13
147. Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE, Hall SD. 2000. Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. Biochem. Pharmacol. 60:7-17
148. Hisamuddin IM, Whebi MA, Chao A, Wyre HW, Hylind LM, et al. 2004. Genetic polymorphisms of human flavin-containing monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin. Cancer Res. 10:8357-62
149. Barnett CR, Gibson GG, Wolf CR, Flatt PR, Ioannides C. 1990. Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes. Biochem. J. 268:765-69
150. Iziar A, Barnett CR, Flatt PR, Ioannides C. 1995. Defective expression of cy tochrome P450 proteins in the liver of the genetically obese Zucker rat. Eur. J. Pharmacol. 293:358-93
151. Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C. 1992. Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. Biochem. Pharmacol. 43:1255-61
152. Barnett CR, Flatt PR, Ioannides C. 1994. Modulation of the rat hepatic cytochrome P450 composition by long-term streptozotocin-induced insulin-dependent diabetes. J. Biochem. Toxicol. 9:63-69
153. Wang T, Shanker K, Ronis MJ, Mehendale HM. 2000. Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1. J. Pharmacol Exp. Ther. 294:473-79
154. Thummel KE, Schenkman JB. 1990. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol. Pharmacol. 37:119-29
155. Shimojo N, Ishizaki T, Imaoka S, Funae Y, Fujii S, et al. 1993. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem. Pharmacol 46:621-27
156. Rouer E, Beaune P, Leroux JP. 1986. Immunoquantitation of some cytochrome P-450 isozymes in live microsomes from streptozotocin-diabetic rats. Experientia 42:1162-63
157. Barnett CR, Rudd S, Flatt PR, Ioannides C. 1993. Sex differences in the diabetes-induced modulation of rat hepatic cytochrome P450 proteins. Biochem. Pharmacol. 26:313-19
158. Yamazoe Y, Murayama N, Shimada M, Imaoka S, Funae Y, Kato R. 1989. Supression of hepatic levels of an ethanol-inducible P-450DM/j by growth hormone: relationship between the increased level of 450DM/J and depletion of growth hormone in diabetes. Mol. Pharmacol. 36:716-22
159. Rouer E, Roupet P, Leroux JP. 1987. Aldrin epoxidase activity in liver micromoses from normal or streptozotocin-diabetic rats: comparision with activity in isolated hepatocytes from normal rats incubated with glucagons. Biosci. Rep. 7:129-33
160. Rouer E, Roupet P, Delpech M, Leroux JP. 1988. Purification and comparison of liver microsomal flavin-containing monooxygenase from normal and streptozotocin-diabetic rats. Biochem. Pharmacol. 37:3455-59
161. Rouer E, Mahu JL, Columelli S, Dansette P, Leroux JP. 1982. Induction of drug metabolizing enzymes in the liver of diabetic mice. Biochimie 64:961-67
162. Rouer E, Lemoine AM, Cresteil T, Rouet P, Leroux JP. 1987. Effects of genetic or chemically induced diabetes on imipramine metabolism. Respective involvement of flavin monooxygenase and cytochrome P-450-dependent monooxygenases. Drug Metab. Dispos. 15:524-28
163. Benowitz NL, Jacob P 3rd. 1994. Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin. Pharmacol. Ther. 56:483-93
164. Beckett AH, Gorrod JW, Jenner P. 1970. Absorption of (-)-nicotine-1-N- oxide in man and its reduction in the gastrointestinal tract. J. Pharm. Pharmacol. 22:722-23
165. Ayesh R, Al-Waiz M, Crothers J, Cholerton S, Mitchell SC, et al. 2005. Deficient nicotine N-oxidation in two sisters with trimethylaminuria. Br. J. Clin. Pharmacol. 25:664P-65
166. Gourlay SG, Kenkare S, Benowitz NL. 2002. Effects of the menstrual cycle on nicotine pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 71:P33 (Abstr.)
167. Cholerton S, Ayesh R, Idle JR, Smith RL. 1988. The pre-eminence of nicotine N-oxidation and its diminution after carbamizole administration. Br. J. Clin. Pharmacol 26:652-53P
168. Jenner P, Gorrod JW. 1973. Comparative in vitro hepatic metabolism of some tertiary N-methyl tobacco alkaloids in various species. Res. Commun. Chem. Pathol. Pharmacol. 6:829-43
169. Beckett AH, Sheikh AH. 1973. Proceedings: in vitro metabolic N-oxidation of the minor tobacco alkaloids, (-) methylanabasine and (-) anabasine to yield a hydroxylamine and a nitrone in lung and liver homogenates. J. Pharm. Pharmacol. 25(Suppl.):171P
170. Hibberd AR, Gorrod JW. 1985. Comparative N-oxidation of nicotine and cotinine by hepatic microsomes. In Biological Oxidation of Nitrogen in Organic Molecules, eds. JW Gorrod, LA Damani, pp. 246-50. Chichester, UK: Ellis Horwood
171. Byrd GD, Chang KM, Greene JM, de Bethizy JD. 1992. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3′-hydroxycotinine in smokers. Drug Metab. Dispos. 20:192-97
172. Yi JM, Sprouse CT, Bowman ER, McKennis H Jr. 1977. The interrelationship between the metabolism of (S)-cotinine-N-oxide and (S)-cotinine. Drug Metab. Dispos. 5:355-62
173. Rodrigues AD, Kukulka MJ, Ferrero JL, Cashman JR. 1995. In vitro hepatic metabolism of ABT-418 in chimpanzee (Pan troglodytes). A unique pattern of microsomal flavin-containing monooxygenase-dependent stereoselective N′-oxidation. Drug Metab. Dispos. 23:1143-52
174. Denton TT, Zhang X, Cashman JR. 2005. 5-substituted, 6-substituted, and unsubstituted 3-heteroaromatic pyridine analogues of nicotine as selective inhibitors of cytochrome P-450 2A6. J. Med. Chem. 48:224-39